HYE REE CHO

Dr. HYE REE CHO

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
JKJaeyoon Kim
Jaeyoon Kim
YNYoojin Nam
Yoojin Nam
PHPa Hong
Pa Hong
HCHYE REE CHO
HYE REE CHO
YKYangWon Kim
YangWon Kim
Background and Objectives: Three-dimensional (3D) coils offer stable initial framing in intracranial aneurysm embolization, but their utility in pulmonary and visceral vascular lesions has not been well established. The objective of this study was to assess the feasibility, safety, and effectiveness of 3D coils used as the primary framing device in pulmonary and visceral embolization. Materials and Methods: This retrospective study included 13 patients with 14 lesions, comprising seven pulmonary arteriovenous malformations (PAVMs), six splenic artery aneurysms (SAAs), and one hepatic artery pseudoaneurysm (HAP), treated between 2024 and 2025. In all lesions, a 0.018-inch 3D coil was deployed as the initial framing coil, followed by further packing with additional 3D or non-3D coils. Technical success, angiographic success, and clinical outcomes were evaluated. Results: Technical success was achieved in all lesions (14/14, 100%; 95% CI, 78.5–100). Angiographic success was achieved in 13 of 14 lesions (92.9%; 95% CI, 68.5–98.7), and clinical success was achieved in 12 of 13 lesions (92.3%; 95% CI, 66.7–98.6). Post-embolization syndrome (PES) developed in five patients with SAAs and in one patient with HAP; all complications were minor and resolved with conservative management. No coil migration or major complications occurred. Conclusions: When used as the initial framing device, 3D coils were technically feasible and achieved acceptable short-term angiographic and clinical outcomes in this small, heterogeneous series; these preliminary findings require confirmation in comparative studies.

19 August 2026 in Chest
Verified
Journal Article
Closed access
YNYoojin Nam
Yoojin Nam
HCHYE REE CHO
HYE REE CHO
EKEunji Kim
Eunji Kim
NKNak Gyeong Ko
Nak Gyeong Ko
PHPa Hong
Pa Hong
HCHyun Kyu Cho
Hyun Kyu Cho

5 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HCHYE REE CHO
HYE REE CHO
YNYoojin Nam
Yoojin Nam
PHPa Hong
Pa Hong
YKYangwon Kim
Yangwon Kim
Background/Objectives: May–Thurner syndrome (MTS) is a common cause of iliofemoral deep vein thrombosis (DVT). Venous bleeding associated with MTS is extremely rare and has been reported mainly as spontaneous iliac vein rupture (SIVR) with retroperitoneal or iliac hematoma. Additionally, standardized treatment strategies have not yet been established. Herein, we report a case of an iliac hematoma associated with MTS that was successfully treated with endovascular mechanical thrombectomy and bare-metal stenting. Case Presentation: A 69-year-old man presented with acute swelling and pain in the left lower extremity. Computed tomography angiography demonstrated extensive iliofemoral DVT and an iliac hematoma adjacent to the left common iliac vessels, without definite evidence of iliac vein rupture. Initial conservative management with anticoagulation therapy was selected as the patient was hemodynamically stable and showed no active bleeding. However, follow-up imaging one week later revealed persistent DVT with interval enlargement of the hematoma. Pelvic arteriography excluded an arterial bleeding source. Endovascular treatment was performed, including mechanical thrombectomy using the AngioJet system and bare-metal stent placement to restore venous outflow. Follow-up imaging revealed complete thrombus resolution, hematoma regression, and sustained stent patency. Conclusions: Iliac hematomas associated with MTS may occur without definite radiological evidence of iliac vein rupture. In selected hemodynamically stable patients, an individualized endovascular strategy focused on venous outflow restoration using the AngioJet system and bare metal stents may be a feasible treatment option.